Prior to joining the U.K.-based medtech company, Bitar served as CEO of agricultural biotech company Genus, holding the corner office position for approximately eight years.
Before his time with Genus, Bitar spent 15 years in various roles with Eliy Lilly, serving as prez of Europe, Australia and Canada.
“I am delighted to announce Karim’s appointment as chief executive officer of ConvaTec. He is an experienced and highly regarded leader with an excellent track record of delivering impressive results and transformational change within similar businesses. The board and I are very confident that Karim is the right person to lead ConvaTec through the next stage of the company’s development,” board chair Christopher Gent said in a press release.
“ConvaTec competes in attractive chronic care markets and has a solid portfolio of products and services. I am excited by the opportunity to lead ConvaTec to stronger and sustainable rates of profitable growth. ConvaTec has the potential to achieve market leadership across its franchises, by focusing on innovation and execution excellence and by leveraging its global presence,” Bitar said in a prepared statement.
Monarch Medical Technologies said yesterday that it named Bruce Lisanti as its new prez & CEO, replacing Linda Beneze who retired from the position.
Prior to joining the Charlotte, N.C.-based company, Lisanti has held leadership positions with a number of high-growth technology companies, including GE.
“On behalf of the board, we first would like to thank Linda Beneze for her contributions while leading Monarch and wish her all the best in her retirement. To continue the execution of the company’s vision, we are pleased to announce the appointment of Bruce Lisanti. With his extensive experience leading high-growth healthcare technology companies, Bruce is well-equipped to take the helm of Monarch and drive the continued advancement of the EndoTool Glucose Management system to help providers improve their clinical and financial outcomes through effective glycemic management,” Eigen Capital Holdings managing member Christophe Mallard said in a press release.
“I’m very excited to be joining Monarch at this moment in the healthcare industry and work with this phenomenal team to advance inpatient diabetes care. As more hospitals face financial pressures under value-based care payment models and increased competition with the rise of healthcare consumerism, the need to improve inpatient diabetes care is no longer just what is in the best interest of the patient, but also the provider’s bottom-line. EndoTool is well positioned as a proven solution to enhance the safety of insulin dosing, improve patient outcomes, and reduce the cost of care, benefiting both patients and providers,” Lisanti said in a prepared statement.
Eyre will be replaced by current global businesses prez & senior VP Giuseppe Accogli, the Deerfield, Ill.-based company said in an SEC filing.
Baxter said that Eyre will stay on as a non-executive in an advisory transition to support the transition, and that both Accogli and Eyre have begun to work on transition.
Micron Solutions said last week that its existing CFO, treasurer and secretary Derek Welch has tendered their resignation, effective April 19.
The Fitchburg, Mass.-based company has not yet revealed plans to replace the departing finance head.
Fresenius Medical Care (NYSE:FMS; ETR:FRE) said last week that it named Dr. Frank Maddux as its new global chief medical officer and Dr. Robert Kossmann as its North America chief medical officer as part of the creation of a global medical office within the company.
The Waltham, Mass.-based company said that it is also lifting current Fresenius Kidney Care chief medical officer Dr. Jeffrey Hymes to the position of North American clinical and scientific affairs senior VP.
Fresenius Medical Care said that the newly created global medical office will look to advance teh application of clinical science and help spread knowledge across the company’s international network.
Maddux has been with Fresenius since 2009, and has held positions including clinical & scientific affairs exec VP and Fresenius NA chief medical officer.
Kossmann joined Fresenius in 2014 to oversee clinical research, development and distribution of products and pharmaceuticals within the company throughout North America, the company said.
“The creation of a global medical office under Dr. Maddux’s leadership will help us coordinate the interpretation of clinical science and medical practice patterns on a global basis. Delivering on our commitment to improve the quality of life of people living with kidney disease, Dr. Maddux and his team will pursue evolving medical opportunities, such as a more focused home offering. Dr. Kossmann and our great team of clinical leaders at Fresenius Medical Care North America will work to make an even greater impact through this improved global collaboration and focus on innovation,” Fresenius Medical Care NA CEO Bill Valle said in a press release.